EUVIMEDSkopri EUVIMED
Systematische Übersicht

Pyridostigmine in chronic intestinal pseudo‐obstruction – a systematic review

Bruce D Wilkie iD, Jawed Noori, Michael Johnston, Rodney Woods, James O Keck, Corina Behrenbruch iD

ANZ Journal of Surgery · 2023

DOI: 10.1111/ans.18478 ↗

At a glance

Systematische Übersicht in ANZ Journal of Surgery, 2023. Written by Bruce D Wilkie and 5 co-authors. Institution: Department of Surgery, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia. Major MEDLINE topics: Pyridostigmine Bromide, Intestinal Pseudo-Obstruction. Cited 18 times so far (Crossref); 30 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Chronic intestinal pseudo‐obstruction (CIPO) may be a primary or secondary phenomenon and is often multifactorial. Treatment is largely directed at improving colonic motility. The use of cholinesterase inhibitors such as pyridostigmine has been hypothesized to increase acetylcholine in the bowel, improving symptoms and transit times.

Methods

A systematic review of the use of pyridostigmine in CIPO was conducted using scientific and commercial search engines identifying scientific studies enrolling adult human subjects, published from 2000 to 2022 in the English language.

Results

Four studies were identified including two randomized controlled trials (RCT) and two observational studies. The studies had heterogenous inclusion criteria, dosing regimens and reported outcomes. Two studies were identified as being at high risk of bias. All studies reported improved patient outcomes with use of pyridostigmine, and low rates (4.3%) of mild cholinergic side effects. No major side effects were reported.

Conclusion

The use of pyridostigmine in management of CIPO is biologically plausible due to its ability to increase colonic motility, and early studies on its role are uniformly suggestive of benefit with low side‐effect profile. Four clinical studies have been conducted to date, with small sample sizes, heterogeneity and high risk of bias. Further high‐quality studies are required to enable assessment of pyridostigmine's utility as an effective management strategy in CIPO.

Subjects

MeSH terms (MEDLINE)

Pyridostigmine BromideIntestinal Pseudo-ObstructionAdultHumansGastrointestinal MotilityCholinesterase InhibitorsChronic Disease

Author keywords

chronic intestinal pseudo-obstructioncolorectal surgeryfunctional bowel disordersgeneral surgery

Substances

Pyridostigmine BromideCholinesterase Inhibitors

Authors and institutions

  • Department of Surgery, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
  • Department of Surgery, Eastern Health, Box Hill, Victoria, Australia.
  • The University of Melbourne, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.

ORCID profiles: Bruce D Wilkie, Corina Behrenbruch

Cite

APA

Wilkie, B. D., Noori, J., Johnston, M., Woods, R., Keck, J. O., & Behrenbruch, C. (2023). Pyridostigmine in chronic intestinal pseudo‐obstruction – a systematic review. ANZ Journal of Surgery. https://doi.org/10.1111/ans.18478

Vancouver

Wilkie BD, Noori J, Johnston M, Woods R, Keck JO, Behrenbruch C. Pyridostigmine in chronic intestinal pseudo‐obstruction – a systematic review. ANZ Journal of Surgery. 2023. doi:10.1111/ans.18478

BibTeX
@article{Wilkie2023,
  author = {Wilkie, Bruce D and Noori, Jawed and Johnston, Michael and Woods, Rodney and Keck, James O and Behrenbruch, Corina},
  title = {Pyridostigmine in chronic intestinal pseudo‐obstruction – a systematic review},
  journal = {ANZ Journal of Surgery},
  year = {2023},
  doi = {10.1111/ans.18478}
}
Start for free →